synbiointel.com exists to provide the clearest, most comprehensive window into the synthetic biology and advanced synbio industry. We believe that the deployment of SMRs will be one of the most consequential energy shifts of the 21st century — and that the people building, funding, licensing, and deploying these platforms deserve a dedicated intelligence platform.
Our mission is to serve synbio engineers, venture capitalists, utility executives, energy analysts, and policy researchers who need to stay ahead of this rapidly evolving industry. We track platform specifications, FDA regulatory milestones, funding rounds, CRISPR fuel supply, pipeline timelines, and data center synbio deals in real time.
synbiointel.com uses advanced AI models to assist in drafting, summarizing, and structuring content at scale. However, all published articles undergo review by our editorial team for accuracy, context, and fairness. We cite primary sources, disclose when information is uncertain, and correct errors promptly.
Our platform database, regulatory pipeline, and company profiles are maintained through a combination of public filings, FDA dockets, press releases, and direct company communications. Specification data may lag real-world developments and we always indicate the "last updated" date.
Our agent monitors 30+ RSS feeds spanning SynBio Newswire, Nature Biotechnology, STAT News, FDA press releases, NIH funding announcements, and bioRxiv — plus 80+ targeted Google News queries covering every major synthetic biology company globally. Runs every hour, around the clock.
Stories that pass our relevance scoring (freshness, significance, novelty) are drafted by Claude, Anthropic's frontier model. Each article synthesizes the source material into concise, factual intelligence — citing primary sources and flagging uncertainty where it exists.
Qualifying articles are published directly to the site within the hour. The platform database, company profiles, funding dashboard, regulatory pipeline, and deployment tracker are maintained through a combination of primary sources, FDA dockets, press releases, and SEC filings.
The fastest way to reach us is on X. We read every mention and DM. For partnerships, data submissions, and press enquiries, email us directly.
info@synbiointel.com@SynBioIntelHQ